Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Clinical Outcomes of Primary Cementless Total Hip Arthroplasty Using the Collarless Actis Stem

14. september 2026 oppdatert av: Young-Kyun Lee, Seoul National University Bundang Hospital

Prospective Cohort Study of Primary Cementless Total Hip Arthroplasty Using Actis Stems

This study looks at how well a hip replacement using the collarless Actis stem works over five years.

Total hip replacement is a common operation for people whose hip joint has been damaged by arthritis, by loss of blood supply to the hip bone, or by a broken hip. During the operation, the damaged parts of the hip are replaced with artificial parts. The Actis stem is the part that is fitted into the thigh bone. It is designed to bond directly with the bone, without the use of bone cement.

The Actis stem is already used in many countries, and early results have been good. However, almost all of those results come from Western patients, and most studies used a version of the stem that has a small collar. Very little is known about how the collarless version performs in Asian patients, who tend to be younger at the time of surgery and more often have the operation because of loss of blood supply to the hip bone.

People aged 18 years or older who are already scheduled for a hip replacement at this hospital may take part. Everyone who takes part has the same operation, with the same set of artificial parts. No extra tests are done for research purposes.

After surgery, participants return to the clinic at 6 weeks, 3 months, and 12 months, and then once a year until 5 years have passed. These are the same visits that patients would have anyway. At each visit, the study team checks for any problems with the new hip, takes routine X-rays, and asks participants to fill in questionnaires about their hip pain, their daily activities, and their overall health.

The main question the study asks is how many participants have a problem with the new hip within five years, such as the hip coming out of place, an infection, a break in the bone around the implant, or the implant becoming loose.

Studieoversikt

Detaljert beskrivelse

The collarless Actis stem is a cementless femoral component featuring a proximal DUOFIX hydroxyapatite coating and a triple-tapered geometry, intended to enhance proximal bone remodeling, promote favorable load distribution, and limit stress shielding. Favorable short-term outcomes have been reported by the manufacturer and in registry-based analyses, and a comparative series has shown results similar to those of the Corail stem. These data, however, derive almost entirely from Western populations, and the majority of published series have evaluated the collared version of the implant. No study has reported the outcomes of the collarless Actis stem in an East Asian population, in whom osteonecrosis of the femoral head is a more frequent indication for arthroplasty and the mean age at the time of surgery is lower than in Western cohorts.

All participants undergo primary cementless ceramic-on-ceramic total hip arthroplasty using the collarless Actis femoral stem and the Pinnacle acetabular cup, with a fourth-generation BIOLOX delta ceramic head and liner. Hybrid use of implants or ceramic bearings is precluded in order to avoid bias. All procedures are performed through a posterior approach with the patient in the lateral decubitus position. Component positioning follows a combined anteversion technique using anatomical landmarks, with a target cup anteversion of 37.3 degrees minus 0.7 times the stem anteversion.

At the routine preoperative medical clearance, participants are assessed for age, sex, body mass index, ambulatory function graded by the Koval classification, diagnosis, comorbidities, and operative risk according to the American Society of Anesthesiologists classification. Preoperative imaging comprises a three-dimensional computed tomography scan of the hip for planning, together with hip anteroposterior, hip cross-table lateral, pelvis lateral, and lumbosacral spine radiographs. Operative data include operative time, type of anesthesia, estimated blood loss, implant fixation, cup position, intraoperative complications, and length of hospital stay.

Postoperative mobilization begins on the first or second day after surgery, and participants ambulate with partial weight bearing using a walking aid for six weeks. Follow-up is scheduled at 6 weeks, 3 months, and 12 months after surgery and annually thereafter until 5 years, corresponding to the institution's routine postoperative schedule. No additional examinations are performed for research purposes beyond those obtained in routine care.

Serial hip anteroposterior and cross-table lateral radiographs are assessed for implant fixation, ceramic wear, osteolysis, implant loosening, and heterotopic ossification according to previously established criteria. Radiographic evaluation is performed by two independent observers who did not participate in the operations, with the six-week radiographs serving as the baseline for comparison. Patient-reported outcome measures are obtained preoperatively and at one year postoperatively and annually thereafter, and comprise the modified Harris Hip Score, the Hip Disability and Osteoarthritis Outcome Score, the EQ-5D, the University of California Los Angeles activity score, and the Forgotten Joint Score, the last of which is acquired postoperatively only.

The target enrollment of 210 hips was derived from an a priori power analysis. Assuming a complication rate of 6.5 percent, based on the investigators' previously reported 10- to 12-year outcomes of fourth-generation ceramic-on-ceramic total hip arthroplasty using the Pinnacle cup, 178 hips were required to detect a 2 percent difference with 80 percent power at a two-sided alpha of 0.05. Allowing for a 15 percent dropout rate, enrollment was set at 210 hips.

Data are recorded in an electronic case report form using a web-based REDCap platform and are monitored every six months for safety and data quality. Categorical data are summarized as counts and percentages and continuous data as means with standard deviations. Implant survivorship is analyzed using the Kaplan-Meier method with reoperation or revision as the endpoint.

Studietype

Intervensjonell

Registrering (Antatt)

210

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Sør -Korea, 13620
        • Rekruttering
        • Seoul National University Bundang Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Age 18 years or older
  • Scheduled to undergo primary total hip arthroplasty for one of the following: osteoarthritis of the hip, developmental dysplasia of the hip, rheumatoid arthritis, non-rheumatoid inflammatory arthritis, post-traumatic arthritis, osteonecrosis of the femoral head, or displaced femoral neck fracture
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Age under 18 years
  • Total hip arthroplasty performed with a femoral stem other than the collarless Actis stem
  • Severe medical comorbidity precluding participation
  • Unwilling to participate in the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Actis
Participants undergo primary cementless total hip arthroplasty using the collarless Actis femoral stem with a Pinnacle acetabular cup and a fourth-generation ceramic-on-ceramic bearing, performed through a posterior approach with the patient in the lateral decubitus position.
Primary cementless total hip arthroplasty using the collarless Actis femoral stem and Pinnacle acetabular cup (DePuy Synthes, Warsaw, IN, USA) with a fourth-generation BIOLOX delta ceramic head and liner (CeramTec, Plochingen, Germany).

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of orthopedic complications
Tidsramme: Up to 5 years after the index total hip arthroplasty
Number of participants with any orthopedic complication, defined as dislocation, periprosthetic joint infection, aseptic loosening, or periprosthetic fracture.
Up to 5 years after the index total hip arthroplasty

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Reoperation rate
Tidsramme: Up to 5 years after the index total hip arthroplasty
Number of participants undergoing any reoperation or revision of the index hip for any reason.
Up to 5 years after the index total hip arthroplasty
Implant survivorship
Tidsramme: Up to 5 years after the index total hip arthroplasty
Kaplan-Meier survivorship of the implant with reoperation or revision for any reason as the endpoint.
Up to 5 years after the index total hip arthroplasty
Modified Harris Hip Score
Tidsramme: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
Modified Harris Hip Score, a measure of hip pain and function ranging from 0 to 100, with higher scores indicating better hip function.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
Hip Disability and Osteoarthritis Outcome Score (HOOS)
Tidsramme: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
HOOS, a patient-reported measure scored from 0 to 100 in each subscale, with higher scores indicating fewer symptoms and better function.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
EQ-5D index score
Tidsramme: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
EQ-5D health-related quality of life index, with higher scores indicating better health status.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
University of California Los Angeles (UCLA) activity score
Tidsramme: Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
UCLA activity score, ranging from 1 to 10, with higher scores indicating a higher level of physical activity.
Preoperatively and at 1, 2, 3, 4, and 5 years after surgery
Forgotten Joint Score (FJS)
Tidsramme: 1, 2, 3, 4, and 5 years after surgery
Forgotten Joint Score, ranging from 0 to 100, with higher scores indicating greater ability to forget the artificial joint in everyday life. Acquired postoperatively only.
1, 2, 3, 4, and 5 years after surgery
Radiographic findings
Tidsramme: 6 weeks to 5 years after surgery
Number of participants with radiographic evidence of implant loosening, osteolysis, ceramic wear, or heterotopic ossification on serial hip anteroposterior and cross-table lateral radiographs, assessed by two independent observers who did not participate in the operations. Six-week radiographs serve as the baseline for comparison.
6 weeks to 5 years after surgery
Incidence of medical complications
Tidsramme: Up to 5 years after the index total hip arthroplasty
Number of participants with deep vein thrombosis, pulmonary embolism, major adverse cardiac events, or death.
Up to 5 years after the index total hip arthroplasty

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Young-Kyun Lee, MD, Seoul National University Bundang Hospital

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. juni 2025

Primær fullføring (Antatt)

30. juni 2031

Studiet fullført (Antatt)

31. desember 2031

Datoer for studieregistrering

Først innsendt

14. september 2026

Først innsendt som oppfylte QC-kriteriene

14. september 2026

Først lagt ut (Faktiske)

18. september 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data are the property of the sponsor institution and are subject to confidentiality obligations under the research support agreement. There is no plan to share individual participant data.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere